Endocrine

, Volume 43, Issue 3, pp 535–538 | Cite as

Hormonal male contraception: end of a dream or start of a new era?

Viewpoint

References

  1. 1.
    A. Brodmerkel, Schonfrist für Spermien. Frankfurter Rundschau, 27 Sep 2012, p. 23 (2012)Google Scholar
  2. 2.
    D.J. Patanelli, Hormonal control of male infertility. Bethesda US Department of Health, Education and Welfare. National Institutes of Health. Publication No. (NIH) 1978; 78, 1097 (1978)Google Scholar
  3. 3.
    G.M.H. Waites, Developments of methods of male contraception: impact of the World Health Organisation Task Force. Fertil. Steril. 80, 1–15 (2003)PubMedCrossRefGoogle Scholar
  4. 4.
    E. Nieschlag, R. Sitruk-Ware, N. Kumar, 7α-Methyl-19-nortestosterone (MENTR): the Population Council’s contribution to research on male contraception and treatment of hypogonadism. Contraception (2012). doi: 10.1016/j.contraception.2012.08.036
  5. 5.
    N.R. Farnsworth, D.P. Waller, Current status of plant products reported to inhibit sperm. Res. Front. Fertil. Regul. 2, 1–16 (1982)PubMedGoogle Scholar
  6. 6.
    T.G. Cooper, C.H. Yeung, Pharmacological approaches to male contraception, in Andrology: Male Reproductive Health and Dysfunction, 3rd edn., ed. by E. Nieschlag, H.M. Behre, S. Nieschlag (Springer, Heidelberg, 2010), pp. 589–599Google Scholar
  7. 7.
    E. Nieschlag, H.M. Behre, The essential role of testosterone in hormonal male contraception, in Testosterone: Action, Deficiency, Substitution, 4th edn., ed. by E. Nieschlag, H.M. Behre (Cambridge University Press, Cambridge, 2012), pp. 479–539CrossRefGoogle Scholar
  8. 8.
    E. Nieschlag, Clinical trials in male hormonal contraception (review). Contraception 82, 457–470 (2010)PubMedCrossRefGoogle Scholar
  9. 9.
    A. Barfield, J. Melo, E. Coutinho et al., Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters. Contraception 20, 121–127 (1979)PubMedCrossRefGoogle Scholar
  10. 10.
    World Health Organization Task Force on Methods for the Regulation of Male Fertility, Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336, 955–959 (1990)CrossRefGoogle Scholar
  11. 11.
    World Health Organization Task Force on Methods for the Regulation of Male Fertility, Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil. Steril. 65, 821–829 (1996)Google Scholar
  12. 12.
    Y.-Q. Gu, X.-H. Wang, D. Xu et al., A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J. Clin. Endocrinol. Metab. 88, 562–568 (2003)PubMedCrossRefGoogle Scholar
  13. 13.
    Y. Gu, X. Liang, W. Wu et al., Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J. Clin. Endocrinol. Metab. 94, 1910–1915 (2009)PubMedCrossRefGoogle Scholar
  14. 14.
    J.C. Soufir, G. Meduri, A. Ziyyat, Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method. Hum. Reprod. 26, 1708–1714 (2011)PubMedCrossRefGoogle Scholar
  15. 15.
    L. Turner, A.J. Conway, M. Jiminez et al., Contraceptive efficacy of a depot gestagen and androgen combination in men. J. Clin. Endocrinol. Metab. 88, 4659–4667 (2003)PubMedCrossRefGoogle Scholar
  16. 16.
    WHO, Controlled trials register NET-EN plus TU as a male contraceptive. (WHO-HRP ID A25165, 2005). http://www.who.int/reproductive-health/rhl/a25165.html
  17. 17.
    WHO Laboratory Manual for the Examination and Processing of Human Sperm, 5th edn. (WHO, Geneva, 2010)Google Scholar
  18. 18.
    C. Mallidis, T.G. Cooper, B. Hellenkemper, M. Lablans, F. Ückert, E. Nieschlag, Ten years experience with an external quality control programme for semen analysis. Fertil. Steril. 98, 611–616 (2012)PubMedCrossRefGoogle Scholar
  19. 19.
    B. Lemcke, H.M. Behre, E. Nieschlag, Frequently subnormal semen profiles of normal volunteers recruited over 17 years. Int. J. Androl. 20, 144–152 (1997)PubMedCrossRefGoogle Scholar
  20. 20.
    E. Nieschlag, E. Vorona, M. Wenk, A.K. Hemker, A. Kamischke, M. Zitzmann, Hormonal male contraception in men with normal and subnormal semen parameters. Int. J. Androl. 34, 556–567 (2011)PubMedCrossRefGoogle Scholar
  21. 21.
    P.Y. Liu, R.S. Swerdloff, P.D. Christenson, D.J. Handelsman, C. Wang, Hormonal Male Contraception Summit Group: rate, extent and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 367, 1412–1420 (2006)PubMedCrossRefGoogle Scholar
  22. 22.
    P.Y. Liu, R.S. Swerdloff, B.D. Anawalt, R.A. Anderson, W.J. Bremner, J. Elliesen, Y.Q. Gu, W.M. Kersemaekers, R.I. McLachlan, M.C. Meriggiola, E. Nieschlag, R. Sitruk-Ware, K. Vogelsong, X.H. Wang, F.C. Wu, M. Zitzmann, D.J. Handelsman, C. Wang, Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J. Clin. Endocrinol. Metab. 93, 1774–1783 (2008)PubMedCrossRefGoogle Scholar
  23. 23.
    K. Heinemann, F. Saad, M. Wiesemes, S. White, L. Heinemann, Attitudes toward male fertility control: results of a multinational survey on four continents. Hum. Reprod. 20, 549–556 (2005)PubMedCrossRefGoogle Scholar
  24. 24.
    S. von Eckardstein, G. Noe, V. Brache et al., International Committee for Contraception Research, The Population Council: a clinical trial of 7alpha-methyl-19-nortestosterone implants for possible use as a longacting contraceptive for men. J. Clin. Endocrinol. Metab. 88, 5232–5239 (2003)CrossRefGoogle Scholar
  25. 25.
    N. Ilani, M.Y. Roth, J.K. Amory, R.S. Swerdloff, C. Dart, S.T. Page, W.J. Bremner, R. Sitruk-Ware, N. Kumar, D.L. Blithe, C. Wang, A new combination of testosterone and nestorone transdermal gels for male hormonal contraception. J. Clin. Endocrinol. Metab. 97, 3476–3486 (2012). doi: 10.1210/jc.2012-1384 PubMedCrossRefGoogle Scholar
  26. 26.
    E. Mommers, W.M. Kersemaekers, J. Elliesen et al., Male hormonal contraception: a double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 93, 2572–2580 (2008)PubMedCrossRefGoogle Scholar
  27. 27.
    http://conrad.org/contraception-trials.html (2012). Accessed 21 Sep 2012
  28. 28.
    A. Kamischke, T. Heuermann, K. Krüger et al., An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J. Clin. Endocrinol. Metab. 87, 530–539 (2002)PubMedCrossRefGoogle Scholar
  29. 29.
    M.C. Meriggiola, A. Costantino, F. Saad et al., Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. J. Clin. Endocrinol. Metab. 90, 2005–2014 (2005)PubMedCrossRefGoogle Scholar
  30. 30.
    G. Benagiano, C. Bastianelli, M. Farris, Contraception: a social revolution. Eur. J. Contracept. Reprod. Health Care. 12, 3–12 (2007)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Centre for Reproductive Medicine and AndrologyUniversity of MünsterMünsterGermany

Personalised recommendations